PCDHGA10 Inhibitors
PCDHGA10 inhibitors are compounds designed to target the Protocadherin Gamma A10 (PCDHGA10), a member of the protocadherin family that is involved in cell adhesion processes. The development of these inhibitors is a complex process that starts with a deep understanding of the molecular structure and function of PCDHGA10. This protein plays a role in the mediation of cell-cell connections in the nervous system, influencing cellular arrangements and signaling pathways. The identification of molecules that can inhibit PCDHGA10 involves comprehensive structural analysis, often utilizing advanced techniques like cryo-electron microscopy or X-ray crystallography to visualize the protein at the atomic level. This structural insight is crucial for identifying potential binding sites where inhibitors can interact with the protein, disrupting its normal function. The process involves the synthesis of various chemical compounds followed by in vitro assays to evaluate their ability to bind to PCDHGA10 and inhibit its activity. This phase is critical for determining the efficacy of the inhibitors and involves a series of optimization steps to enhance their specificity and binding affinity.
The optimization of PCDHGA10 inhibitors is a meticulous process that employs structure-activity relationship (SAR) studies to refine the chemical structure of the compounds for maximal efficacy and specificity. By systematically modifying the chemical structure of the compounds and evaluating the resultant effect on PCDHGA10 inhibition, researchers can identify the most effective inhibitors. This iterative process involves both the synthesis of new compounds and the detailed biochemical characterization of their interaction with PCDHGA10. Techniques such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are often used to measure the binding affinity of the inhibitors to the protein, providing quantitative data that guides further modifications. Additionally, computational methods, including molecular docking and dynamic simulations, play a pivotal role in predicting how modifications to the inhibitor's structure might influence its interaction with PCDHGA10. These combined approaches ensure the development of highly specific inhibitors that target PCDHGA10 effectively, minimizing the likelihood of off-target interactions and ensuring a high degree of precision in their mechanism of action.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisphenol A | 80-05-7 | sc-391751 sc-391751A | 100 mg 10 g | $300.00 $490.00 | 5 | |
Bisphenol A is a chemical compound used in the production of plastics. It can potentially inhibit PCDHGA10 by acting as an endocrine disruptor and interfering with hormone signaling pathways. Bisphenol A has been shown to bind to estrogen receptors and modulate gene expression, which can indirectly affect the expression and function of PCDHGA10. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a nucleoside analog that can inhibit DNA methyltransferases, enzymes responsible for adding methyl groups to DNA. By inhibiting DNA methylation, 5-Azacytidine can potentially affect the epigenetic regulation of PCDHGA10 expression. DNA methylation patterns can influence gene expression, and alterations in DNA methylation can lead to changes in PCDHGA10 expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a potent inhibitor of histone deacetylases (HDACs), enzymes that remove acetyl groups from histone proteins, affecting gene expression. HDAC inhibitors can modulate the expression of genes, including PCDHGA10, by increasing histone acetylation and promoting a more open chromatin structure, allowing for increased transcriptional activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 [Z-Leu- Leu-Leu-CHO] is a reversible inhibitor of the proteasome, a cellular complex responsible for protein degradation. By inhibiting the proteasome, MG-132 [Z-Leu- Leu-Leu-CHO] can potentially increase the stability and accumulation of PCDHGA10 protein, leading to enhanced expression and function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a selective inhibitor of the PI3K/AKT signaling pathway, which is involved in cell survival and proliferation. By inhibiting PI3K/AKT signaling, LY 294002 can potentially influence the downstream signaling cascades that regulate PCDHGA10 expression and function. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4 is a selective inhibitor of the histone demethylase JMJD3. By inhibiting JMJD3, GSK-J4 can potentially affect the epigenetic regulation of PCDHGA10 expression. JMJD3 is known to demethylate histone H3 lysine 27 (H3K27), and inhibition of this demethylase can lead to altered gene expression patterns. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö 6976 is a selective inhibitor of protein kinase C (PKC), a family of serine/threonine kinases involved in various cellular processes. PKC can regulate gene expression and signal transduction pathways. By inhibiting PKC, Gö 6976 can potentially influence the signaling pathways that regulate PCDHGA10 expression and function. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine is a nucleoside analog that can inhibit DNA methyltransferases, enzymes responsible for adding methyl groups to DNA. By inhibiting DNA methylation, 5-Aza-2′-Deoxycytidine can potentially affect the epigenetic regulation of PCDHGA10 expression. Alterations in DNA methylation can lead to changes in gene expression patterns. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is a selective inhibitor of protein kinase A (PKA), a serine/threonine kinase involved in various cellular processes. PKA can regulate gene expression and signal transduction pathways. By inhibiting PKA, H-89 dihydrochloride can potentially influence the signaling pathways that regulate PCDHGA10 expression and function. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3 Inhibitor XVI is a selective inhibitor of glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase involved in various cellular processes, including gene expression regulation. By inhibiting GSK-3, GSK-3 Inhibitor XVI can potentially affect the signaling pathways that regulate PCDHGA10 expression and function. | ||||||